NABCO ‘Celebrates Life’ and Honors Breast Cancer Survivors at Luncheon

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

NEW YORK-Wearing pink roses, more than 100 breast cancer survivors toasted each other at the National Alliance of Breast Cancer Organizations’ Celebrate Life luncheon, hosted by Academy Award winning actress Mira Sorvino.

NEW YORK—Wearing pink roses, more than 100 breast cancer survivors toasted each other at the National Alliance of Breast Cancer Organizations’ Celebrate Life luncheon, hosted by Academy Award winning actress Mira Sorvino.

At the luncheon, NABCO presented its Celebrate Life award to two women—Julia Child, culinary author, teacher, and television personality, who is a 30-year breast cancer survivor, and Catherine Viscardi Johnston, executive vice president of The Condé Nast Publications and a recent breast cancer survivor.

“Scientists and activists have changed the face of breast cancer in the time spanning the diagnoses of NABCO’s two honorees,” said Amy S. Langer, NABCO’s executive director and a 14-year breast cancer survivor. “Thirty years ago, breast cancer meant losing your breast and, too often, your life. Today, early detection and treatment advances mean that most women diagnosed are treated and go on with life—a life suddenly more precious, with much to celebrate.”

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content